Mitigating Inflammation Using Advanced Drug Delivery By Targeting TNF-α in Lung Diseases

Future Medicinal ChemistryVol. 14, No. 2 EditorialMitigating inflammation using advanced drug delivery by targeting TNF-α in lung diseasesSabya Sachi Das, Sandeep Kumar Singh, PRP Verma, Niraj Kumar Jha, Piyush Kumar Gupta & Kamal DuaSabya Sachi Das https://orcid.org/0000-0002-4042-8525Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, 835215, Ranchi, Jharkhand, India, Sandeep Kumar Singh **Author for correspondence: E-mail Address: sandeep.singh@bitmesra.ac.inhttps://orcid.org/0000-0001-5702-4554Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, 835215, Ranchi, Jharkhand, India, PRP Verma https://orcid.org/0000-0002-7980-9616Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, 835215, Ranchi, Jharkhand, India, Niraj Kumar Jha https://orcid.org/0000-0001-9486-4069Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, 201310, Uttar Pradesh, India, Piyush Kumar Gupta *Author for correspondence: E-mail Address: piyush.kumar1@sharda.ac.inhttps://orcid.org/0000-0002-3346-910XDepartment of Life Science, School of Basic Sciences & Research (SBSR), Sharda University, Knowledge Park III, Greater Noida, 201310, Uttar Pradesh, India & Kamal Dua https://orcid.org/0000-0002-7507-1159Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, AustraliaAustralian Research Centre in Complementary & Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, AustraliaPublished Online:3 Nov 2021https://doi.org/10.4155/fmc-2021-0225AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: inflammatory cytokinespulmonary inflammatory diseasestargeted drug deliveryTNF-αReferences1. Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin. Arthritis Rheum. 40(2), 147–163 (2010).Crossref, Medline, CAS, Google Scholar2. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNF-α in pulmonary pathophysiology. Respir. Res. 7, 125 (2006).Crossref, Medline, Google Scholar3. Thomas PS. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol. Cell Biol. 79(2), 132–140 (2001).Crossref, Medline, CAS, Google Scholar4. Malaviya R, Laskin JD, Laskin DL. Anti-TNF-α therapy in inflammatory lung diseases. Pharmacol. Ther. 180, 90–98 (2017).Crossref, Medline, CAS, Google Scholar5. Gong K, Guo G, Beckley N et al. Tumor necrosis factor in lung cancer: complex roles in biology and resistance to treatment. Neoplasia 23(2), 189–196 (2021).Crossref, Medline, CAS, Google Scholar6. Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E, Sanlioglu S. Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer 44(2), 199–211 (2004).Crossref, Medline, Google Scholar7. Tobinick E. TNF-α inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr. Med. Res. Opin. 20(1), 39–40 (2004).Crossref, Medline, CAS, Google Scholar8. Ye W, Lu S, Xue A. The potential role of TNF-α in 2019 novel coronavirus pneumonia. Respir. Med. Case Rep. 30, 101087 (2020).Medline, Google Scholar9. Ti H, Zhou Y, Liang X, Li R, Ding K, Zhao X. Targeted treatments for chronic obstructive pulmonary disease (COPD) using low-molecular-weight drugs (LMWDs). J. Med. Chem. 62(13), 5944–5978 (2019).Crossref, Medline, CAS, Google Scholar10. Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox. Biol. 33, 101544 (2020).Crossref, Medline, CAS, Google Scholar11. Sharma P, Mehta M, Dhanjal DS et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem. Biol. Interact. 309, 108720 (2019).Crossref, Medline, CAS, Google Scholar12. Harrell CR, Sadikot R, Pascual J et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives. Stem Cells Int. 2019, 4236973 (2019).Crossref, Medline, Google Scholar13. Lee AY, Cho MH, Kim S. Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy. Expert Opin. Drug Deliv. 16(7), 757–772 (2019).Crossref, Medline, CAS, Google Scholar14. Masaoutis C, Mihailidou C, Tsourouflis G, Theocharis S. Exosomes in lung cancer diagnosis and treatment. From the translating research into future clinical practice. Biochimie 151, 27–36 (2018).Crossref, Medline, CAS, Google Scholar15. Koli U, Krishnan RA, Pofali P, Jain R, Dandekar P. SiRNA-based therapies for pulmonary diseases. J. Biomed. Nanotechnol. 10(9), 1953–1997 (2014).Crossref, Medline, CAS, Google Scholar16. Mehta M, Deeksha, Tewari D et al. Oligonucleotide therapy: an emerging focus area for drug delivery in chronic inflammatory respiratory diseases. Chem. Biol. Interact. 308, 206–215 (2019).Crossref, Medline, CAS, Google Scholar17. Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct. Target Ther. 4, 61 (2019).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByMolecular insights and therapeutic implications of nanoengineered dietary polyphenols for targeting lung carcinoma: part INanomedicine, Vol. 17, No. 23Redistribution of TNF Receptor 1 and 2 Expression on Immune Cells in Patients with Bronchial Asthma24 May 2022 | Cells, Vol. 11, No. 11 Vol. 14, No. 2 Follow us on social media for the latest updates Metrics Downloaded 58 times History Received 6 August 2021 Accepted 14 October 2021 Published online 3 November 2021 Published in print January 2022 Information© 2021 Newlands PressKeywordsinflammatory cytokinespulmonary inflammatory diseasestargeted drug deliveryTNF-αFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download